20068101

Source:http://linkedlifedata.com/resource/pubmed/id/20068101

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003250, umls-concept:C0018270, umls-concept:C0030705, umls-concept:C0031327, umls-concept:C0036043, umls-concept:C0086418, umls-concept:C0205179, umls-concept:C0227525, umls-concept:C0280100, umls-concept:C0851347, umls-concept:C1879711, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2010-1-15
pubmed:abstractText	The aims were to assess the safety, pharmacokinetics, maximum tolerated dose, and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/SF)-neutralizing monoclonal antibody, in patients with solid tumors.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Hepatocyte Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/rilotumumab
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1078-0432
pubmed:author	pubmed-author:AndersonAbrahamA, pubmed-author:BeaupreDarrin MDM, pubmed-author:BranstetterDanielD, pubmed-author:BurgessTeresa LTL, pubmed-author:CoxonAngelaA, pubmed-author:DengHongjieH, pubmed-author:EckhardtS GailSG, pubmed-author:GordonMichael SMS, pubmed-author:GoreLiaL, pubmed-author:JinY AYA, pubmed-author:Kaplan-LefkoPaulaP, pubmed-author:LeitchIan MIM, pubmed-author:MendelsonDavid SDS, pubmed-author:OlinerKelly SKS, pubmed-author:SweeneyChristopher SCS, pubmed-author:YanLucyL
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	16
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	699-710
pubmed:meshHeading	pubmed-meshheading:20068101-Adult, pubmed-meshheading:20068101-Aged, pubmed-meshheading:20068101-Animals, pubmed-meshheading:20068101-Antibodies, Monoclonal, pubmed-meshheading:20068101-Antineoplastic Agents, pubmed-meshheading:20068101-Disease Progression, pubmed-meshheading:20068101-Dose-Response Relationship, Drug, pubmed-meshheading:20068101-Drug Resistance, Neoplasm, pubmed-meshheading:20068101-Female, pubmed-meshheading:20068101-Hepatocyte Growth Factor, pubmed-meshheading:20068101-Humans, pubmed-meshheading:20068101-Male, pubmed-meshheading:20068101-Maximum Tolerated Dose, pubmed-meshheading:20068101-Mice, pubmed-meshheading:20068101-Middle Aged, pubmed-meshheading:20068101-Neoplasms, pubmed-meshheading:20068101-Tumor Cells, Cultured, pubmed-meshheading:20068101-Xenograft Model Antitumor Assays, pubmed-meshheading:20068101-Young Adult
pubmed:year	2010
pubmed:articleTitle	Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
pubmed:affiliation	Premiere Oncology of Arizona, Scottsdale, Arizona 85258, USA. mgordon@premiereoncology.com
pubmed:publicationType	Journal Article, Clinical Trial, Phase I